Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulrik Lassen

Showing results (11-20 of 159) with videos related to

Pageof 16
Sort By:
Trials|December 13, 2019
Criteria for site selection in industry-sponsored clinical trials: a survey among decision-makers in biopharmaceutical companies and clinical research organizationsTilde Dombernowsky, Merete Haedersdal, Ulrik Lassen, et al.
BMJ Open|July 13, 2017
Development in the number of clinical trial applications in Western Europe from 2007 to 2015: retrospective study of data from national competent authoritiesTilde Dombernowsky, Merete Hædersdal, Ulrik Lassen, et al.
Pharmacology Research & Perspectives|June 13, 2017
Clinical trial allocation in multinational pharmaceutical companies - a qualitative study on influential factorsTilde Dombernowsky, Merete Haedersdal, Ulrik Lassen, et al.
Cancer Investigation|May 28, 2010
Cetuximab insufficiently inhibits glioma cell growth due to persistent EGFR downstream signalingBenedikte Hasselbalch, Ulrik Lassen, Hans S Poulsen, et al.
Journal of Neuro-Oncology|November 28, 2012
Phase II open-label study of nintedanib in patients with recurrent glioblastoma multiformeAida Muhic, Hans Skovgaard Poulsen, Morten Sorensen, et al.
The Lancet. Oncology|November 5, 2020
Dabrafenib plus trametinib in patients with BRAF<sup>V600E</sup>-mutated biliary tract cancer - Authors' replyVivek Subbiah, Ulrik Lassen, Eduard Gasal, et al.
Cells|July 25, 2025
A High-Throughput ImmunoHistoFluorescence (IHF) Method for Sub-Nuclear Protein Analysis in TissueKezia Catharina Oxe, Kristoffer Staal Rohrberg, Ulrik Lassen, et al.
Anticancer Research|April 9, 2013
Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiformeUlrik Lassen, Morten Sorensen, Tine Bernhardtsen Gaziel, et al.
Anticancer Research|September 21, 2012
A phase I study of concurrent chemoradiotherapy and cetuximab for locally advanced esophageal cancerCecilie Holländer, Lene Baeksgaard, Morten Sorensen, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 7, 2011
Preoperative staging of lung cancer with PET/CT: cost-effectiveness evaluation alongside a randomized controlled trialRikke Søgaard, Barbara Malene B Fischer, Jann Mortensen, et al.
Pageof 16

Showing results (11-20 of 159) with videos related to

Sort By:
Pageof 16
Trials|December 13, 2019
Criteria for site selection in industry-sponsored clinical trials: a survey among decision-makers in biopharmaceutical companies and clinical research organizationsTilde Dombernowsky, Merete Haedersdal, Ulrik Lassen, et al.
BMJ Open|July 13, 2017
Development in the number of clinical trial applications in Western Europe from 2007 to 2015: retrospective study of data from national competent authoritiesTilde Dombernowsky, Merete Hædersdal, Ulrik Lassen, et al.
Pharmacology Research & Perspectives|June 13, 2017
Clinical trial allocation in multinational pharmaceutical companies - a qualitative study on influential factorsTilde Dombernowsky, Merete Haedersdal, Ulrik Lassen, et al.
Cancer Investigation|May 28, 2010
Cetuximab insufficiently inhibits glioma cell growth due to persistent EGFR downstream signalingBenedikte Hasselbalch, Ulrik Lassen, Hans S Poulsen, et al.
Journal of Neuro-Oncology|November 28, 2012
Phase II open-label study of nintedanib in patients with recurrent glioblastoma multiformeAida Muhic, Hans Skovgaard Poulsen, Morten Sorensen, et al.
The Lancet. Oncology|November 5, 2020
Dabrafenib plus trametinib in patients with BRAF<sup>V600E</sup>-mutated biliary tract cancer - Authors' replyVivek Subbiah, Ulrik Lassen, Eduard Gasal, et al.
Cells|July 25, 2025
A High-Throughput ImmunoHistoFluorescence (IHF) Method for Sub-Nuclear Protein Analysis in TissueKezia Catharina Oxe, Kristoffer Staal Rohrberg, Ulrik Lassen, et al.
Anticancer Research|April 9, 2013
Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiformeUlrik Lassen, Morten Sorensen, Tine Bernhardtsen Gaziel, et al.
Anticancer Research|September 21, 2012
A phase I study of concurrent chemoradiotherapy and cetuximab for locally advanced esophageal cancerCecilie Holländer, Lene Baeksgaard, Morten Sorensen, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 7, 2011
Preoperative staging of lung cancer with PET/CT: cost-effectiveness evaluation alongside a randomized controlled trialRikke Søgaard, Barbara Malene B Fischer, Jann Mortensen, et al.
Pageof 16